Progress has been made by using small interference RNA (siRNA) to knock down CIP2A expression in breast cancer cells and NSCLC (non-small cell lung cancer) cells, both decreasing the tumorigenic potentials of the cancer cells and sensitizing them to chemotherapy [136,141]. The gene discussed is CIP2A; the disease is non-small cell lung carcinoma.